Biontech Se ADR (BNTX)

$96.73 +0.33 (0.34%)
Market Cap 24.46B
Revenue (ttm) 3.25B
Net Income (ttm) -1.29B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39.59%
Debt to Equity Ratio 0.02
Volume 1,176,600
Avg Vol 1,243,146
Day's Range N/A - N/A
Shares Out 252.88M
Stochastic %K 9%
Beta 1.29
Analysts Strong Sell
Price Target $122.00

Company Profile

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin a...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
1dayatadime
1dayatadime Sep. 14 at 1:56 PM
$BNTX algos will pick it up and double/triple it
0 · Reply
healthmaster
healthmaster Sep. 14 at 1:49 PM
$BNTX i got a feeling that this will goes to 92$+ before it'll want to go parabolic, to accumulate and generate shorts, short is literally 1% float at the moments.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 14 at 1:42 PM
$BNTX LOL Just hold and add if possible. WS crooks at their best. JMO
0 · Reply
wintogether
wintogether Sep. 14 at 1:12 PM
$BNTX for this stock the pre-market volume is quite high given its usual history. Expect this to run to 120 today. Might dip in the morning for a buyable dip.
2 · Reply
OpenOutcrier
OpenOutcrier Sep. 14 at 12:29 PM
$BNTX (+6.2% pre) BioNTech drug shows doubled survival in lung cancer trial https://ooc.bz/l/114051
0 · Reply
Hunchinvestor
Hunchinvestor Sep. 14 at 12:24 PM
$BNTX why not trending
1 · Reply
1dayatadime
1dayatadime Sep. 14 at 12:08 PM
$BNTX almost 100% improvement
0 · Reply
Moin77
Moin77 Sep. 14 at 12:02 PM
$BNTX next Stop 115$
0 · Reply
JayAr3
JayAr3 Sep. 14 at 12:00 PM
$BNTX 'Survival Benefit: Median overall survival reached 18.5 months with gotistobart, compared to just 10.0 months for standard-of-care chemotherapy.' That is quite sad, that we're talking about months here. Still an improvement.
0 · Reply
wintogether
wintogether Sep. 14 at 11:52 AM
$BNTX why was there no PR from Biontech about the Pumitamig+elfetabart results?
0 · Reply
Latest News on BNTX
BioNTech, OncoC4 announce first median overall survival data from PRESERVE-003

2026-09-14T09:10:13.000Z - 4 hours ago

BioNTech, OncoC4 announce first median overall survival data from PRESERVE-003

BioNTech says lung cancer drug candidate prolonged lives in trial

Sep 14, 2026, 4:07 AM EDT - 5 hours ago

BioNTech says lung cancer drug candidate prolonged lives in trial

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

Sep 14, 2026, 4:00 AM EDT - 5 hours ago

BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients

BioNTech downgraded to Market Perform from Outperform at BMO Capital

2026-09-08T08:50:14.000Z - 6 days ago

BioNTech downgraded to Market Perform from Outperform at BMO Capital

BioNTech price target lowered to $136 from $142 at Canaccord

2026-08-31T11:05:30.000Z - 14 days ago

BioNTech price target lowered to $136 from $142 at Canaccord

BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why

2026-08-28T16:15:00.000Z - 16 days ago

BioNTech Stock (BNTX) Is Tumbling on Friday – Here’s Why

MRK MRNA

Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital

2026-08-28T16:10:13.000Z - 16 days ago

Cevumeran trial termination a ‘clear setback’ for BioNTech, says BMO Capital

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

2026-08-28T14:55:25.000Z - 16 days ago

mRNA immunotherapy discontinuation a negative for BioNTech, says Morgan Stanley

MRK MRNA

BioNTech to terminate mid-stage trial of mRNA cancer vaccine

Aug 28, 2026, 9:41 AM EDT - 17 days ago

BioNTech to terminate mid-stage trial of mRNA cancer vaccine

BioNTech drops 9% after ending Phase 2 colorectal cancer trial

2026-08-28T13:20:17.000Z - 17 days ago

BioNTech drops 9% after ending Phase 2 colorectal cancer trial

BioNTech to terminate Phase 2 monotherapy trial of cevumeran

2026-08-28T13:10:11.000Z - 17 days ago

BioNTech to terminate Phase 2 monotherapy trial of cevumeran

US FDA approves updated COVID vaccines for 2026-27 season

Aug 27, 2026, 5:48 PM EDT - 17 days ago

US FDA approves updated COVID vaccines for 2026-27 season

MRNA NVAX PFE SNY

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

2026-08-27T20:35:15.000Z - 17 days ago

Pfizer and BioNTech receive FDA approval for XFG-adapted COVID-19 vaccine

PFE

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

Aug 27, 2026, 4:30 PM EDT - 17 days ago

Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine

PFE

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

Aug 20, 2026, 5:30 AM EDT - 25 days ago

BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026

BioNTech rises 20.3%

2026-08-19T16:05:37.000Z - 25 days ago

BioNTech rises 20.3%

BioNTech rises 21.6%

2026-08-19T14:00:12.000Z - 25 days ago

BioNTech rises 21.6%

BioNTech price target lowered to $130 from $135 at Evercore ISI

2026-08-05T14:23:35.000Z - 5 weeks ago

BioNTech price target lowered to $130 from $135 at Evercore ISI

BioNTech price target raised to $142 from $138 at Canaccord

2026-08-05T11:05:37.000Z - 5 weeks ago

BioNTech price target raised to $142 from $138 at Canaccord

BioNTech SE Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Earnings Call Transcript: Q2 2026

BioNTech SE Earnings release: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Earnings release: Q2 2026

BioNTech SE Slides: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 5 weeks ago

BioNTech SE Slides: Q2 2026

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

Aug 4, 2026, 7:12 AM EDT - 5 weeks ago

Why Pfizer Stock and This Covid Vaccine Partner Are Falling on Earnings

PFE

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

Aug 4, 2026, 7:02 AM EDT - 5 weeks ago

BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

Aug 4, 2026, 6:45 AM EDT - 5 weeks ago

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

BioNTech says Sobi's Oelkers will replace Sahin as CEO

Aug 3, 2026, 5:29 AM EDT - 6 weeks ago

BioNTech says Sobi's Oelkers will replace Sahin as CEO

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Aug 3, 2026, 5:00 AM EDT - 6 weeks ago

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Jul 29, 2026, 4:30 PM EDT - 6 weeks ago

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

PFE

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

Jul 21, 2026, 6:45 AM EDT - 7 weeks ago

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Jul 3, 2026, 1:51 AM EDT - 2 months ago

BioNTech held buyer talks over four German sites set to close, Handelsblatt reports

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

Jun 17, 2026, 2:38 AM EDT - 2 months ago

Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO

MRNA

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

May 30, 2026, 2:15 PM EDT - 3 months ago

Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

This Biotech's Cancer Portfolio Could End Its Rough Patch

May 27, 2026, 11:07 AM EDT - 3 months ago

This Biotech's Cancer Portfolio Could End Its Rough Patch

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

May 22, 2026, 5:00 AM EDT - 3 months ago

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

May 15, 2026, 4:15 PM EDT - 4 months ago

BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026

BioNTech SE Transcript: AGM 2026

May 15, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Transcript: AGM 2026

BioNTech Announces New ADS Repurchase Program

May 7, 2026, 6:45 AM EDT - 4 months ago

BioNTech Announces New ADS Repurchase Program

Germany says vaccine supply secure despite BioNTech production loss

May 6, 2026, 7:44 AM EDT - 4 months ago

Germany says vaccine supply secure despite BioNTech production loss

BioNTech SE Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings Call Transcript: Q1 2026

BioNTech SE Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Earnings release: Q1 2026

BioNTech SE Slides: Q1 2026

May 5, 2026, 8:00 AM EDT - 4 months ago

BioNTech SE Slides: Q1 2026

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

May 5, 2026, 7:26 AM EDT - 4 months ago

BioNTech to Close Sites, Cut Quarter of Workforce in Savings Push

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

May 5, 2026, 6:47 AM EDT - 4 months ago

BioNTech to close sites in Germany, Singapore affecting 1,860 staff

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

May 5, 2026, 6:45 AM EDT - 4 months ago

BioNTech Announces First Quarter 2026 Financial Results and Corporate Update

Two experimental drugs showed striking early results against pancreatic cancer

Apr 21, 2026, 5:35 PM EDT - 4 months ago

Two experimental drugs showed striking early results against pancreatic cancer

RVMD

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

Apr 21, 2026, 6:45 AM EDT - 4 months ago

BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Apr 11, 2026, 7:00 AM EDT - 5 months ago

BioNTech and DualityBio's Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

Apr 1, 2026, 11:39 AM EDT - 5 months ago

Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles

PFE

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Mar 24, 2026, 6:45 AM EDT - 5 months ago

BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 10, 2026, 2:48 PM EDT - 6 months ago

BioNTech SE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

One simple reason why BioNTech stock is a raging buy on today's crash

Mar 10, 2026, 1:29 PM EDT - 6 months ago

One simple reason why BioNTech stock is a raging buy on today's crash

BioNTech SE Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings Call Transcript: Q4 2025

BioNTech SE Annual report: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Annual report: Q4 2025

BioNTech SE Earnings release: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Earnings release: Q4 2025

BioNTech SE Slides: Q4 2025

Mar 10, 2026, 8:00 AM EDT - 6 months ago

BioNTech SE Slides: Q4 2025

Scientists behind COVID-19 vaccine will depart BioNTech

Mar 10, 2026, 7:40 AM EDT - 6 months ago

Scientists behind COVID-19 vaccine will depart BioNTech

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

Mar 10, 2026, 7:18 AM EDT - 6 months ago

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock.

BioNTech Cofounders to Leave to Form New Company

Mar 10, 2026, 6:50 AM EDT - 6 months ago

BioNTech Cofounders to Leave to Form New Company

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

Mar 10, 2026, 6:49 AM EDT - 6 months ago

BioNTech's founding couple Sahin, Tuereci to leave to set up new venture

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

Mar 10, 2026, 6:45 AM EDT - 6 months ago

BioNTech Announces Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

Mar 10, 2026, 6:33 AM EDT - 6 months ago

BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

Feb 24, 2026, 6:45 AM EST - 6 months ago

BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026

BioNTech sues Moderna for patent infringement over COVID-19 shots

Feb 19, 2026, 1:25 PM EST - 6 months ago

BioNTech sues Moderna for patent infringement over COVID-19 shots

MRNA

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

Jan 28, 2026, 8:00 AM EST - 7 months ago

BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 8 months ago

BioNTech SE Transcript: 44th Annual J.P. Morgan Healthcare Conference

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 5:15 PM EST - 8 months ago

BioNTech SE Slides: 44th Annual J.P. Morgan Healthcare Conference

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 6:45 AM EST - 8 months ago

BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

Jan 9, 2026, 10:00 AM EST - 8 months ago

University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

Dec 18, 2025, 4:45 AM EST - 9 months ago

BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

Dec 9, 2025, 7:00 AM EST - 9 months ago

BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer

BMY

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

Dec 6, 2025, 3:30 PM EST - 9 months ago

BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

Dec 3, 2025, 9:01 AM EST - 9 months ago

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

CVAC

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 9 months ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

MRNA NVAX PFE

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 9 months ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

MRNA NVAX PFE

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Nov 26, 2025, 7:30 AM EST - 9 months ago

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 10 months ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

PFE

1dayatadime
1dayatadime Sep. 14 at 1:56 PM
$BNTX algos will pick it up and double/triple it
0 · Reply
healthmaster
healthmaster Sep. 14 at 1:49 PM
$BNTX i got a feeling that this will goes to 92$+ before it'll want to go parabolic, to accumulate and generate shorts, short is literally 1% float at the moments.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 14 at 1:42 PM
$BNTX LOL Just hold and add if possible. WS crooks at their best. JMO
0 · Reply
wintogether
wintogether Sep. 14 at 1:12 PM
$BNTX for this stock the pre-market volume is quite high given its usual history. Expect this to run to 120 today. Might dip in the morning for a buyable dip.
2 · Reply
OpenOutcrier
OpenOutcrier Sep. 14 at 12:29 PM
$BNTX (+6.2% pre) BioNTech drug shows doubled survival in lung cancer trial https://ooc.bz/l/114051
0 · Reply
Hunchinvestor
Hunchinvestor Sep. 14 at 12:24 PM
$BNTX why not trending
1 · Reply
1dayatadime
1dayatadime Sep. 14 at 12:08 PM
$BNTX almost 100% improvement
0 · Reply
Moin77
Moin77 Sep. 14 at 12:02 PM
$BNTX next Stop 115$
0 · Reply
JayAr3
JayAr3 Sep. 14 at 12:00 PM
$BNTX 'Survival Benefit: Median overall survival reached 18.5 months with gotistobart, compared to just 10.0 months for standard-of-care chemotherapy.' That is quite sad, that we're talking about months here. Still an improvement.
0 · Reply
wintogether
wintogether Sep. 14 at 11:52 AM
$BNTX why was there no PR from Biontech about the Pumitamig+elfetabart results?
0 · Reply
notreload_ai
notreload_ai Sep. 14 at 11:37 AM
$BNTX and OncoC4 report gotistobart nearly doubled median overall survival versus docetaxel in relapsed squamous NSCLC. Confirmatory trial continues. https://notreload.xyz/xy/biontech-drug-nearly-doubles-survival-in-squamous-lung-cancer/
0 · Reply
htw7448
htw7448 Sep. 14 at 9:29 AM
$BNTX so $BNTX presented 2 breakthroughs on one weekend
0 · Reply
htw7448
htw7448 Sep. 14 at 9:27 AM
$BNTX Gotistobart doubles survival time -> new standard of care soon
0 · Reply
ToRni27
ToRni27 Sep. 14 at 7:41 AM
$BNTX i could get some at $96.88 this night xD lets see! Waiting for pre and regular! Give me $120 plz!
0 · Reply
YOLODiamondHand
YOLODiamondHand Sep. 14 at 1:03 AM
$BNTX very curious what is the price action tmr 🤔
0 · Reply
JessTaylor22
JessTaylor22 Sep. 13 at 9:07 PM
$BNTX Also at WCLC… In unresectable malignant mesothelioma, in first-line pumitamig (BNT327/BMS-986545) plus chemotherapy, the updated Phase 2 analysis reported: * confirmed ORR: 51.6% * disease-control rate: 93.5% * median PFS: 16.6 months * median OS: 25.8 months
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 13 at 7:28 PM
$BNTX There should be another readout in WCLC 2026 from BNTX. The interim data from PRESERVE Phase 3 (Gotistobart) for squamous NSCLC. If that readout is good, we are going to make a major bank. Is that right? JMO
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 13 at 5:02 PM
$BNTX MRNA's success against melanoma is like a child's play when compared to BNTX's success against small call lung cancer. The mRNA method has been used successfully against skin cancer for some time. The medical field knows about it. But SCLC is very tough. BNTX's P 1/2b data are not just great. It is wildly beyond what has been expected for SCLC. It is groundbreaking. Anyone who wants to downplay is either intentionally lying or extremely ignorant. JMO
3 · Reply
fredbull
fredbull Sep. 13 at 4:22 PM
$BNTX triple from here
1 · Reply
wintogether
wintogether Sep. 13 at 2:57 PM
$BNTX obviously happy for my small holdings here, but really hopeful for the patients and the field. These guys are proving to be the best in class.
0 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:34 AM
$BNTX PD-L1 x VEGF-A bispecific antibody plus B7H3 antibody-drug conjugate show 70.4% ORR
0 · Reply
eightytwentie
eightytwentie Sep. 13 at 3:32 AM
$BNTX data lookin real gooood
0 · Reply